ClinicalTrials.gg
CompletedNCT03509454PROTONUpdated Apr 26, 2018

PeRsOnalising Treatment Of Diabetic Nephropathy:

An observational study in Diabetes Mellitus, Type 1, Diabetes Complications and Diabetic Nephropathies, sponsored by Peter Rossing. Completed at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-26.

Sponsored by Peter Rossing · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
210
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark — 30 open to participants now, 35 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · Denmark.

Enrollment
18th of 38
210 · median 175
Started
2016
with 9 others
Observational
39 of 196
10 open now
Registered
104th of 196
by date

Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, this one is the 18th largest by enrollment of the 38 observational ones that give a count, is one of 10 that started in 2016, is one of 39 observational ones, and was the 104th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

30 of the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, or all of them as a file.
02

Study summary

Background: Today diabetic nephropathy is a frequent, and the most lethal and costly complication of diabetes. Although treating blood pressure with agents blocking renin angiotensin system has improved outcome, the prognosis is still poor and no new interventions have been successful during the past decade. There is an urgent need for discovery of new pathways behind the development and progression of diabetic nephropathy as well as of biomarkers which can identify subjects at risk of developing adverse events. Objective: By using a multidimensional 'omics' approach, we aim to search for novel proteins, metabolites and pathways that will point to the putative new mechanisms which underlie the early renal decline.

Design: Cross-sectional study, with long-term register-based follow-up. Study population: 160 patients with type 1 diabetes recruited from Steno Diabetes Center Copenhagen stratified based on stage of diabetic kidney disease, and 50 healthy non-diabetic controls. Endpoints: Primary endpoint: Glycocalyx thickness, assessed as perfused boundary region. Secondary endpoints: Gut microbiome characterisation and markers of gastrointestinal inflammation, autonomic and periphery neuropathy, urine and plasma Flow Cytometry Analysis (FACS), metabolomics and proteomics in plasma and urine, and other potential biomarkers.

Read the detailed description

Design: Cross-sectional study, with long-term register-based follow-up. Study population: 160 patients with type 1 diabetes recruited from Steno Diabetes Center Copenhagen stratified based on stage of diabetic kidney disease, and 50 healthy non-diabetic controls. Endpoints: Primary endpoint: Glycocalyx thickness, assessed as perfused boundary region. Secondary endpoints: Gut microbiome characterisation and markers of gastrointestinal inflammation, autonomic and periphery neuropathy, urine and plasma Flow Cytometry Analysis (FACS), metabolomics and proteomics in plasma and urine, and other potential biomarkers.

03

Conditions studied

  • Diabetes Mellitus, Type 1
  • Diabetes Complications
  • Diabetic Nephropathies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

160 patients with type 1 diabetes and different stages of diabetic nephropathy (50 with normoalbuminuria; 50 with microalbuminuria; and 60 with macroalbuminuria -including at least 30 with concurrent estimated Glomerular Filtration Rate (eGFR) \< 60 ml/min/1.73m2) compared to 50 healthy non-diabetic controls.

Eligibility criteria

Inclusion Criteria:

  • Patients with type 1 diabetes
  • Written must be provided before participation
  • Male or female patients >18 years of age with a diagnosis of type 1 diabetes (WHO criteria)
  • Persistent urinary albumin creatinine ratio (UACR) assessed from EPJ (Electronic Patient Journal):
  • \< 30 mg/g in 2 out of 3 consecutive samples (normoalbuminuria)
  • 30 - 299 mg/g in 2 out of 3 consecutive samples (microalbuminuria)
  • ≥ 300 mg/g in 2 out of 3 consecutive samples (macroalbuminuria) - at least 30 with concurrent \< 60 ml/min/1.73m2

    1. Control subjects without diabetes
  • Written informed consent must be provided before participation.
  • Male or female patients >18 years of age without a diagnosis of diabetes (assessed by Hb1Ac, and creatinine)

Exclusion Criteria: (Both subjects with and without diabetes)

  • Non-diabetic kidney disease as indicated by medical history and/or laboratory findings
  • Renal failure (eGFR\<15 ml/min/1.73m2), dialysis or kidney transplantation
  • Change in RAAS blocking treatment during the last month
  • Treatment with antibiotics during the last 2 month
  • Pregnancy or breastfeeding (urine HCG is performed on all fertile women)
  • Patients who, in the judgement of the investigator, is incapable to participate
  • For controls: Other diseases or intake of medicine which in the judgement of the investigator could affect the results, specifically renal, cardiovascular or inflammatory/infectious diseases should be considered for exclusion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
210 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Type 1 DM, Normo albuminuric

    Type 1 diabetics with no history of albumnuria (UACR \< 30 mg/g in 2 out of 3 consecutive samples)

  • Type 1 DM, Micro albuminuric

    Type 1 diabetics with history of micro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)

  • Type 1 DM, Macro albuminuric

    Type 1 diabetics with history of macro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)

  • Healthy subjects

    Subjects with no history of diabetes, other diseases or intake of medicine which in the judgement of the investigator could affect the results, specifically renal, cardiovascular or inflammatory/infectious diseases should be considered for exclusion.

06

What researchers measure

Primary outcomes

  1. The microvascular function by estimating the glycocalyx thickness

    Glycocalyx thickness assessed as perfused boundary region by a hand-hold camera (GlycoCheck)

    Time frame: 2019

Secondary outcomes

  1. Gut microbiome

    Characterisation of the gut microbiota and markers of gastrointestinal inflammation

    Time frame: 2019

  2. Urine and plasma Flow Cytometry Analysis (FACS)

    cell types related to inflammation

    Time frame: 2019

  3. Metabolomics in plasma

    metabolite risk score in plasma

    Time frame: 2019

  4. Metabolomics in urine

    metabolite risk score in urine

    Time frame: 2019

  5. proteomics in urine

    proteomic risk score in urine

    Time frame: 2019

  6. proteomics in plasma

    proteomic risk score in plasma

    Time frame: 2019

  7. Autonomic neuropathy

    beat to beat variation (R-R test) upon Deep breathing

    Time frame: 2019

  8. peripheral neuropathy

    vibration perception threshold

    Time frame: 2019

07

Study locations

1 site
  • Steno Diabetes Center
    Gentofte, Copenhagen 2820, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in Oct 2017, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2018
First posted
Apr 26, 2018
StartActual
Apr 1, 2016
Primary completionActual
Oct 1, 2017
CompletionActual
Apr 1, 2018
Last update
Apr 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03509454
Lead sponsor
Peter Rossing
Responsible party
Peter Rossing (Professor, MD, DMsc, Steno Diabetes Center Copenhagen) — Sponsor-investigator
First posted
Apr 26, 2018
Start date
Apr 1, 2016
Primary completion
Oct 1, 2017
Completion
Apr 1, 2018
Last update
Apr 26, 2018

Study contacts

peter Rossing
study chair · Steno Diabetes Center Copenhagen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion